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Abstract
Introduction: The human monoclonal antibody adalimumab is known to induce an anti-globulin response in
some adalimumab-treated patients. Antibodies against adalimumab (AAA) are associated with non-response to
treatment. Immunoglobulins, such as adalimumab, carry allotypes which represent slight differences in the amino
acid sequences of the constant chains of an IgG molecule. Immunoglobulins with particular IgG (Gm) allotypes are
racially distributed and could be immunogenic for individuals who do not express these allotypes. Therefore, we
investigated whether a mismatch in IgG allotypes between adalimumab and IgG in adalimumab-treated patients is
associated with the development of AAA.
Methods: This cohort study consisted of 250 adalimumab-treated rheumatoid arthritis (RA) patients. IgG allotypes
were determined for adalimumab and for all patients. Anti-idiotype antibodies against adalimumab were measured
with a regular radio immunoassay (RIA), and a newly developed bridging enzyme linked immunosorbent assay
(ELISA) was used to measure anti-allotype antibodies against adalimumab. The association between AAA and the
G1m3 and the G1m17 allotypes was determined. For differences between groups we used the independent or
paired samples t-test, Mann-Whitney test or Chi square/Fisher’s exact test as appropriate. To investigate the
influence of confounders on the presence or absence of AAA a multiple logistic regression-analysis was used.
Results: Adalimumab carries the G1m17 allotype. No anti-allotype antibodies against adalimumab were detected.
Thirty-nine out of 249 patients had anti-idiotype antibodies against adalimumab (16%). IgG allotypes of RA patients
were associated with the frequency of AAA: patients homozygous for G1m17 had the highest frequency of AAA
(41%), patients homozygous for G1m3 the lowest frequency (10%), and heterozygous patients’ AAA frequency was
14% (P = 0.0001).
Conclusions: An allotype mismatch between adalimumab and IgG in adalimumab-treated patients did not lead to
a higher frequency of AAA. On the contrary, patients who carried the same IgG allotype as present on the
adalimumab IgG molecule, had the highest frequency of anti-adalimumab antibodies compared to patients whose
IgG allotype differed from adalimumab. This suggests that the allotype of adalimumab may not be highly
immunogenic. Furthermore, patients carrying the G1m17-allotype might be more prone to antibody responses.
Introduction
Treatment with monoclonal antibodies (mAbs) is known
to induce anti-mAb antibodies, leading to a diminished
treatment response [1-5]. The general structure of all
antibodies is very similar; it consists of a constant and a
variable region, the variable region determines the idio-
type. The anti-adalimumab antibodies (AAA) measured
in previous studies are anti-idiotype antibodies, directed
against the idiotype of adalimumab [1,6]. The constant
region is almost identical in all antibodies of the same
isotype, but differs in antibodies of different isotypes
(for example, IgA, IgM, IgG, IgE, IgD). However, within
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an immunoglobulin of a certain isotype, allotypes repre-
sent slight differences in the amino acid sequences of
the constant heavy or light chains of different indivi-
duals (Figure 1) [7]. There are different allotypes for
IgG1, IgG2 and IgG3 and no allotypes have been found
for IgG4. Allotypes are inherited in a codominant Men-
delian way, in fixed combinations called haplotypes.
Allotypes expressed on the constant region of IgG heavy
chain are designated as Gm (Genetic markers) together
with the subclass. Allotypes of heavy g1 chains are
defined as G1m allotypes, allotypes of heavy g2 chains
as G2m allotypes, and of heavy g3 chains as G3m allo-
types. The Gm system is unique in its ability to charac-
terize human populations by specific sets of haplotypes.
Specific Gm haplotypes are found in African, Caucasian
and Mongoloid populations. In a Caucasian population
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Figure 1 Basic immunoglobulin structure and IgG1 allotypes. (a). Basic immunoglobulin structure. CH1, 2 and 3 are the constant heavy
chains. CL is the constant light chain. VH is the variable heavy chain and VL the variable light chain which together form the variable domain of
the immunoglobulin, a specific antigen binding site, also referred to as the idiotype. (b). IgG1 allotypes [7]. The white residues in the constant
parts are those residues which differ by allotype in human IgG1. There is a Lys (G1m17) for Arg (G1m3) change at codon 214 in the CH1
domain, an Asp 356 Leu 358 (G1m1) for Glu 356 Met 358 (nG1m1) in the CH3 domain and a Gly 431 (G1m2) for Ala (nG1m2) also in the CH3
domain. The nG1m1 and nG1m2 are not “true” allotypes because these amino acid residues are present in other IgG subclasses and are not
expected to be immunogenic in the individual.
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the G1m1,17 (or G1m(a,z)) allotype is much less fre-
quent (0.15 to 0.35) than G1m3 (or G1m(f)) (0.65 to
0.85) [8]. Therefore, serologically defined allotypes differ
widely within and between population groups [9].
Allotypic markers can therefore differ between indi-
viduals and immunoglobulins with certain allotypes
can be immunogenic when injected into individuals
whose immunoglobulins lack the allotype. Treatment
with monoclonal antibodies with a certain allotype can
lead to the formation of anti-allotype antibodies. The
allotypes of a panel of licensed mAbs was determined
and adalimumab expresses the G1m1,17-allotype [9].
The risk to provoke antibody responses as a result of
allo-immunization has been described in a review [9].
MAb treatment of patients may lead to both allo-
immunization and/or xeno-immunization that result in
antisera that may recognize isotypic, allotypic and idio-
typic epitopes.
The association between anti-infliximab antibodies
and immunoglobulin allotypes was recently investigated
[10]. Infliximab expresses the G1m1,17-allotype, the
hypothesis of this study was that patients without the
G1m1,17-allotype were more likely to develop anti-
infliximab antibodies. However, no association was
found between the patients’ allotypes and the presence
or concentration of anti-infliximab antibodies. The
authors pose the question whether this would also be
the case for humanized or fully human antibodies,
because in chimeric antibodies the murine variable
domain could dominate the antibody response. This
might not be the case for humanized or human mono-
clonal antibodies.
In this study we investigated whether an IgG allotype
mismatch between adalimumab- and adalimumab-trea-
ted patients is associated with a higher frequency of
AAA.
Materials and methods
Patients
All 250 consecutive unrelated RA patients were included
in a prospective observational cohort at the outpatient
clinics of the Departments of Rheumatology of the Jan
van Breemen Institute and the Academic Medical Cen-
ter in Amsterdam. All patients fulfilled the American
College of Rheumatology 1987 revised criteria for RA
[11], and had active disease, indicated by a disease activ-
ity score in 28 joints (DAS28) of ≥3.2 despite earlier
treatment with two disease modifying anti-rheumatic
drugs (DMARDs) including methotrexate (MTX) at a
dosage of 25 mg weekly or at the maximal tolerable
dosage, according to the Dutch consensus statement on
the initiation and continuation of TNF blocking therapy
in RA [12]. Patients were treated with either adalimu-
mab and concomitant DMARD therapy, or adalimumab
monotherapy. All patients used adalimumab 40 mg sub-
cutaneously every other week. In patients with an inade-
quate response as judged by the treating rheumatologist,
the dosing frequency of adalimumab could be increased
to 40 mg per week. The study was approved by the
Medical Ethics Committee of the Slotervaart Hospital,
BovenIJ Hospital, the Jan van Breemen Institute, and the
Academic Medical Center/University of Amsterdam. All
patients gave written informed consent.
Clinical response to adalimumab
Disease activity was assessed at baseline and after
28 weeks of therapy using the DAS28 score. Clinical
response was assessed by the decrease in DAS28 score
(ΔDAS28) and the European League Against Rheuma-
tism (EULAR) response criteria [13].
The measurement of human IgG1 allotypes
The most prevalent allotypes of the G1m system were
measured: G1m1, G1m3 and G1m17.
Immunoglobulin allotypes were determined by an
enzyme-linked immunosorbent assay (ELISA) using spe-
cific antibodies against Gm markers. All incubations
were at room temperature. Plates were coated for two
hours with 0.5 μg/ml of a mouse monoclonal antibody
to human IgG1 (MH161-1, Sanquin, Amsterdam, The
Netherlands). After washing, the plates were incubated
for one hour with serum of interest, and diluted 1:1000
in PTG buffer (PBS, 0.2% gelatine, 0.02% Tween). After-
ward washing plates were incubated for one hour with
allotype-specific biotinylated monoclonal antibodies. For
that purpose we used anti-G1m3 (%A1), anti-G1m17
(5F10) and anti-G1m1 (MG102-A2 at 10 ng/ml (San-
quin). After washing, the plates were incubated with
polymerTsed streptavidin-horseradish peroxidase (poly-
HRP). Non-bound streptavidin-poly-HRP was removed
by washing and the amount of bound streptavidin was
measured by incubating the plates with tetramethylben-
zidine (TMB), the substrate for HRP. The reaction was
stopped with H2SO4. Absorption at 450 nm was deter-
mined in a microtiter plate reader. The results of the
unknown sera were compared with the sera with known
allotypes.
Measurement of antibodies against adalimumab
Serum samples were collected at baseline and just prior
to an injection with adalimumab after 4, 16 and 28
weeks. The presence of AAA was determined at all time
points between baseline and 28 weeks. AAA were
detected with a radio immunoassay (RIA). One micro
litre of serum diluted in PBS/0.3% bovine serum albu-
min (BSA) (PA buffer) was incubated over night with 1
mg Sepharose-immobilized protein A (GE Healthcare,
Chalfont, St. Giles, UK) in a final volume of 800 μl.
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Subsequently the samples were washed with PBS 0.005%
Tween and specific ADA binding was detected by o/n
incubation with 20.000 dpm (approximately 1 ng) 1,25I
labeled F(ab)2 adalimumab diluted in Freeze buffer
(Sanquin). The unbound label was removed by washing,
and protein A bound radioactivity was measured. When
binding was higher than 25% of the input, sera were
further titrated. Antibody levels were compared to a
standard serum containing anti-drug antibody levels and
expressed in arbitrary units (AU). One AU corresponds
to approximately 12 ng. The mean cut-off value was set
at 12 AU/ml which was derived from 100 healthy
donors. Assay specificity was demonstrated by the
absence of AAA in 25 sera containing high-titres anti-
infliximab antibodies from patients not treated with ada-
limumab. In the assays we did not find cross reactivity.
Recently, patient sera were tested in a bioassay, which
confirmed the specificity and validity of the RIA [14].
Patients were defined as positive for anti-adalimumab
antibodies if titres were above 12 AU/ml on at least one
occasion, in combination with serum adalimumab levels
below 5.0 mg/L. All baseline samples before the start of
treatment were negative.
Measurement of anti-allotype antibodies against
adalimumab/infliximab
We searched for anti-allotype antibodies using a two-
sided assay/bridging ELISA. Sera were tested for their
capacity to make a bridge between coated adalimumab
and biotinylated adalimumab. To that end plates were
coated with 0.5 μg/ml adalimumab in phosphate buf-
fered saline. After washing, the plates were incubated
with patient sera. After washing, the plates were incu-
bated with biotinylated adalimumab at 5 ng/ml. After
washing, the plates were incubated with streptavidin-
poly-HRP and developed as described above. All sera
that were positive in the RIA were also positive in this
bridging ELISA. Adalimumab and infliximab have the
same allotype (G1m1,17). We reasoned that if sera were
positive due to anti-allotype antibodies, these sera
should also be positive if adalimumab was replaced by
infliximab. Therefore, sera were also tested for their
capacity to bridge infliximab with adalimumab and ada-
limumab with infliximab. As controls we used rabbit
anti-adalimumab-idiotype, rabbit anti-infliximab-idiotype
and a monoclonal antibody to human IgG (MH16-1).
Statistical analysis
For statistical analysis SPSS version 16.0 (SPSS Inc., Chi-
cago, Illinois, USA) was used. We chose to analyze the
association among AAA and the G1m3 and the G1m17
allotypes at codon 214 (Figure 1), since these allotypes
correspond with a single amino acid change and haplo-
type construction is not required. For differences
between groups we used the independent or paired sam-
ples t-test, Mann-Whitney test or Chi square/Fisher’s
exact test as appropriate. To investigate the influence of
confounders on the presence or absence of AAA, a mul-
tiple logistic regression-analysis was used. Variables con-
sidered potential confounders were chosen from all
available baseline variables and were determined for
every analysis specifically, based on differences between
groups included in the analysis. Variables were included
in the regression model as confounders if the beta chan-
ged 10% or more after inclusion of the variable in the
model. The threshold for significance was set at
P < 0.05. To analyze clinical response we used the last
observation carried forward for patients who stopped
treatment due to non-response or adverse events, and
for patients who had received increased adalimumab
dosing frequency.
Results
Patient characteristics
Patient characteristics are shown in Table 1. Of the 250
patients enrolled in the study, six (2%) discontinued ada-
limumab treatment after four weeks of therapy, and 16
(6%) stopped treatment after Week 16. Ten patients
(4%) stopped due to treatment failure, nine (4%) because
of adverse events and three (1%) were lost to follow-up.
Twenty-one patients (8%) had an increased dosing fre-
quency before 28 weeks to 40 mg adalimumab per
week; in these patients the last DAS28 before dose
increase was carried forward to 28 weeks.
Clinical response
The mean DAS28 after 28 weeks of adalimumab therapy
decreased from 5.2 ± 1.2 at baseline to 3.7 ± 1.5 (P =
0.0001). There were 63 (25%) non-responders, 105
(42%) moderate responders, and 82 (33%) good respon-
ders according to the EULAR response criteria.
Association between allotypes and anti-adalimumab
antibodies
Thirty-nine out of 249 patients had antibodies against
adalimumab (16%); in one patient AAA could not be
determined. Patients without AAA had a significantly
greater DAS28 improvement than patients with AAA
(ΔDAS28 = 1.7 versus ΔDAS28 = 0.5, P = 0.0001).
Adalimumab and infliximab have the same allotype
G1m1,17 [9,10]. Nevertheless we observed that all sera
positive in the assay for antibodies to adalimumab
(hence the adalimumab-adalimumab combination) were
negative in the assay for anti-infliximab (the infliximab-
infliximab combination) as well as in the assay where
adalimumab was combined with infliximab. The anti-
IgG was strongly positive in all three assays. Our con-
clusion is that these patients do not make anti-allotype
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antibodies and that all AAA’s are due to anti-idiotypic
antibodies.
There was a significant association between the G1m3
and G1m17 allotypes and antibodies against adalimu-
mab (Table 2). After adjustment for MTX dose in logis-
tic regression the carriage of more G1m17 alleles was
significantly associated with a higher frequency of anti-
bodies against adalimumab (P = 0.0001; OR = 2.639;
95% CI = 1.608 to 4.332). Baseline characteristics for the
three groups with G1m3 and G1m17 allotypes are
shown in Table 3.
Discussion
Our hypothesis was that a mismatch between the allo-
type of adalimumab, G1m1,17, and the allotypes of the
IgG of adalimumab treated RA patients would be asso-
ciated with a higher frequency of anti-adalimumab anti-
bodies. This was not the case. The first explanation for
this lack of association could be that neither of the
assays we used was able to detect anti-allotype antibo-
dies. Our RIA for the detection of AAA is designed to
detect anti-idiotype antibodies. In this assay a solution
containing pepsine treated polyclonal IgG Freeze buffer
is added, as a result anti-allotype antibodies are not
detected. However, without Freeze buffer anti-allotype
antibodies also were not detected. No anti-allotype anti-
bodies were detected with the bridging ELISA. It might
be possible that the bridging ELISA was not able to
detect anti-allotype antibodies, due to low titers, epitope
masking or steric hindrance. Another explanation could
be that anti-allotype antibodies are not developed or
that the quantity of the anti-allotype antibody response
is not large enough to be detected. The allotypes of ada-
limumab may not be highly immunogenic, and could be
only a minor antigen compared to the idiotype of adali-
mumab. Patients who were homozygous for G1m3, for
whom the allotype of adalimumab theoretically would
be immunogenic, had a clinical response that did not
differ from patients who carried the G1m17-allotype
after adjustment for having anti-idiotype antibodies
Table 1 Demographic and clinical characteristics at
baseline
Total population
n = 250
Demographics
Age, years 52 ± 13
Female, no. (%) 197 (79)
DMARD therapy
Prior DMARDs (no.) 3.4 ± 1.6
Methotrexate use, no. (%) 199 (80)
Methotrexate dose (mg/wk) 23 (15 to 25)
Prednisone use, no. (%) 82 (33%)
Prednisone dose (mg/day) 7.5 (5 to 10)
Disease status
Disease duration (years) 8 (4 to 17)
Rheumatoid factor positive, no. (%) 179 (72)
Erosive disease, no. (%) 194 (78)
Erythrocyte sedimentation rate (mm/h) 30 ± 23
C-reactive protein (mg/dl) 11 (5 to 24)
DAS28 5.2 ± 1.2
Mean values ± SD, median and interquartile range, or percentages are shown.
DAS28, Disease Activity Score in 28 joints; DMARD, diseases modifying anti
rheumatic drug.
Table 2 Association between G1m3 and G1m17 allotypes
and antibodies against adalimumab
G1m phenotype AAA - AAA +
3,3 108 (90%) 12 (10%)
3,17 83 (86%) 14 (14%)
17,17 19 (59%) 13 (41%)
AAA -, anti-adalimumab antibodies negative; AAA +, anti-adalimumab
antibodies positive.
Patient numbers and corresponding percentages are shown. P = 0.0001 for
the whole table.
Table 3 Demographic and clinical characteristics at
baseline
G1m phenotype
3,3 3,17 17,17
n = 120 n = 98 n = 32
Demographics
Age, years 53 ± 14 53 ± 12* 48 ± 12*
Female, no. (%) 95 (79) 74 (76) 28 (88)
DMARD therapy
Prior DMARDs (no.) 3.5 ± 1.6 3.4 ± 1.7 3.3 ± 1.6
Methotrexate use, no. (%) 95 (79) 81 (83) 23 (72)
Methotrexate dose
(mg/wk)
21 (15 to 25) 25 (15 to 25) 25 (17.5 to
25)
Prednisone use, no. (%) 39 (33) 31 (32) 12 (38)
Prednisone dose (mg/day) 7.5 (5 to 10) 5 (5 to 7.5) 10 (5 to 10)
Disease status
Disease duration (years) 10 (4 to 17) 11 (3 to 16) 7 (3 to 17)
Rheumatoid factor
positive, no. (%)
80 (67)* 70 (71) 29 (91)*
Erosive disease, no. (%) 90 (75) 76 (78) 28 (88)
Erythrocyte sedimentation
rate (mm/h)
29 ± 23 31 ± 25 28 ± 17
C-reactive protein (mg/dl) 11 (4 to 24) 10 (6 to 23) 14 (6 to 31)
DAS28 5.1 ± 1.2 5.3 ± 1.2 5.2 ± 1.0
DAS28, Disease Activity Score in 28 joints; DMARD, diseases modifying anti
rheumatic drug.
*There was a significant difference between patients with the 3,17-allotype
and the 17,17-allotype for age (P = 0.020), and between both homozygous
groups 3,3 and 17,17 for rheumatoid factor positivity, no. (P = 0.007).
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against adalimumab (data not shown). This suggests that
if anti-allotype antibodies had developed, their clinical
relevance would be nil.
Our hypothesis could not be confirmed, but the
results showed an unexpected association between
allotypes and AAA: RA patients whose IgG1 was homo-
zygous for the same allotype as adalimumab, the
G1m17-allotype, had the highest frequency of AAA
compared to G1m3 homozygotes or heterozygotes. This
suggests that the frequency of AAA has no relation with
the possible immunogenicity of the allotype of adalimu-
mab, but is more likely explained by patient-related
genetic factors. A selective force behind the distribution
and inheritance of allotypes may have been the associa-
tion between immunoglobulin allotypes and the specific
antibody responses to pathogens, resulting in differential
immunity to infectious diseases [15]. For numerous
infectious diseases an association has been found
between immunoglobulin allotypes and (the level of)
antibody response [15]. There are several studies in
which the G1m1,17-allotype or a haplotype containing
this allotype was associated with a stronger immune
response compared to individuals with the G1m3-allo-
type. For example, systemic sclerosis patients homozy-
gous for the G1m3 allele were 60% less likely to be
seropositive for IgG antibodies against cytomegalovirus
than patients homozygous for the G1m17 allele or the
heterozygotes [16]. Hepatitis C virus (HCV) infected
patients with the Gm1,17 5,13 phenotype within an
African American population had two-fold higher med-
ian antibody titres against E1 and E2 envelope glycopro-
teins, HCV epitopes than those who lacked this
phenotype [17]. In a study on the association of allo-
types with antibodies against MUC1, a tumor-associated
antigen, gastric cancer patients with the phenotype Gm3
23 5, 13 had lower anti-MUC1-IgG levels compared to
patients without this phenotype [18].
Patients with the G1m3 phenotype not only had AAA
significantly less often, but were also less often positive for
rheumatoid factor (Table 3). This also contributes to the
hypothesis that allotypes are associated with specific anti-
body responses. Individuals with a G1m1,17-allotype
might be more prone to antibody responses than indivi-
duals with the G1m3-allotype. No conclusive data are
available on how allotypes could influence immune
response, albeit several possibilities are mentioned [15].
The locus or loci responsible for the association with
immune response may not be the Gm system itself but
may reflect linkage disequilibrium with other polymorph-
isms of the constant region genes or with specific variable
region genes. There is evidence for a genetic predisposi-
tion to the formation of antibodies. Previously, we showed
that interleukin-10 (IL10) polymorphisms were associated
with anti-adalimumab antibody formation in RA [19].
However, we did not find an association between IL10
polymorphisms and IgG allotypes (data not shown).
Conclusions
To our knowledge this is the first study examining the
association between G1m allotypes and immunogenicity
against adalimumab. Our findings suggest that the allotype
is not a dominant antigen of adalimumab. Albeit we have
to take into account that we did not find anti-allotype anti-
bodies. Interestingly, our data show that anti-adalimumab
antibody formation occurred more often in RA patients
with the G1m17-allotype than in RA patients without this
allotype, which indicates a role for genetic factors. Patients
carrying this allotype might be more prone to antibody
responses. However, these results should be replicated in
larger study populations with a representative variation in
allotypes in order to draw firm conclusions.
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